Compare · ELOX vs SUPN
ELOX vs SUPN
Side-by-side comparison of Eloxx Pharmaceuticals Inc. (ELOX) and Supernus Pharmaceuticals Inc. (SUPN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ELOX focuses on Biotechnology: Biological Products (No Diagnostic Substances), while SUPN focuses on Biotechnology: Pharmaceutical Preparations.
- SUPN is the larger of the two at $2.30B, about 41.6x ELOX ($55.3M).
- Over the past year, ELOX is up 25.6% and SUPN is down 24.6% - ELOX leads by 50.2 points.
- SUPN has been more active in the news (3 items in the past 4 weeks vs 2 for ELOX).
- Both have 7 recent analyst ratings on file.
- Company
- Eloxx Pharmaceuticals Inc.
- Supernus Pharmaceuticals Inc.
- Price
- $12.88-3.56%
- $37.88-4.22%
- Market cap
- $55.3M
- $2.30B
- 1M return
- -27.89%
- -11.80%
- 1Y return
- +25.61%
- -24.56%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2012
- News (4w)
- 2
- 3
- Recent ratings
- 7
- 7
Eloxx Pharmaceuticals Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland.
Latest ELOX
- Cantor Fitzgerald initiated coverage on Eloxx Pharmaceuticals
- SEC Form EFFECT filed by Eloxx Pharmaceuticals Inc.
- Leerink Partners initiated coverage on Eloxx Pharmaceuticals with a new price target
- SEC Form S-1 filed by Eloxx Pharmaceuticals Inc.
- Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
- Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- SEC Form 8-K filed by Eloxx Pharmaceuticals Inc.
- SEC Form 10-Q filed by Eloxx Pharmaceuticals Inc.
- Guggenheim initiated coverage on Eloxx Pharmaceuticals with a new price target
- Large owner Domicilium Real Estate Fund Iii Lp acquired 600,000 shares (SEC Form 4)
Latest SUPN
- SEC Form 8-K filed by Supernus Pharmaceuticals Inc.
- SEC Form 425 filed by Supernus Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Supernus Pharmaceuticals Inc.
- SEC Form DEFM14A filed by Supernus Pharmaceuticals Inc.
- Supernus Pharmaceuticals to Participate in September Investor Conferences
- Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
- President, CEO Khattar Jack A. converted options into 29,849 shares and covered exercise/tax liability with 12,642 shares, increasing direct ownership by 1% to 1,258,351 units (SEC Form 4) to satisfy withholding tax
- SVP, Chief Medical Officer Rubin Jonathan converted options into 750 shares and covered exercise/tax liability with 363 shares, increasing direct ownership by 3% to 13,979 units (SEC Form 4) to satisfy withholding tax
- SVP, Chief Tech. Ops. Officer Mottola Frank converted options into 1,650 shares and covered exercise/tax liability with 797 shares, increasing direct ownership by 5% to 19,544 units (SEC Form 4) (tax liability)
- Sr. VP of IP, CSO Bhatt Padmanabh P. converted options into 2,500 shares and covered exercise/tax liability with 1,158 shares, increasing direct ownership by 8% to 18,637 units (SEC Form 4) (tax withholding)